Leadership Overview
Fresenius Kabi has 8 executives leading key functions including finance, technology, operations, marketing, and regional leadership.
Driven by innovation, Fresenius Kabi is dedicated to advancing patient care through specialized medicines and technologies for infusion, transfusion, and clinical nutrition, impacting global health outcomes.
Driven by innovation, Fresenius Kabi is dedicated to advancing patient care through specialized medicines and technologies for infusion, transfusion, and clinical nutrition, impacting global health outcomes.
Leadership Roles at Fresenius Kabi
Marco Magrassi - Chief Financial Officer
Marco Magrassi, the Chief Financial Officer at Fresenius Kabi, directs global financial strategy and operations. Overseeing all fiscal activities, Magrassi ensures robust financial planning and resource allocation across the organization. This leadership position involves managing budgets, forecasting financial performance, and optimizing capital structure to support Fresenius Kabi's growth objectives in infusion, transfusion, and clinical nutrition markets. By implementing stringent financial controls and driving efficiency, Marco Magrassi strengthens the company's economic foundation. The Chief Financial Officer's oversight extends to financial reporting, investor relations, and risk management, ensuring compliance and fiscal integrity worldwide. Magrassi's strategic financial guidance underpins the company's ability to invest in research and development and expand its global reach.
Christian Mattis - Chief Financial Officer, Medtech NAM
Christian Mattis, the Chief Financial Officer, Medtech NAM at Fresenius Kabi, directs financial operations and strategic planning for the Medtech division within North America. Overseeing all fiscal aspects, Mattis ensures financial health and drives profitable growth across the region's Medtech portfolio. This leadership position involves managing regional budgets, financial forecasting, and optimizing financial performance to support Fresenius Kabi's objectives in North America. By implementing robust financial controls and identifying key investment opportunities, Christian Mattis enhances the Medtech NAM business unit's capabilities. The Chief Financial Officer, Medtech NAM's responsibilities include financial analysis, reporting, and ensuring compliance with regional financial regulations. Mattis's financial acumen is crucial for expanding Fresenius Kabi's Medtech market share.
Alex Garini - Executive Vice President & Chief Financial Officer
Alex Garini, the Executive Vice President & Chief Financial Officer at Fresenius Kabi, provides overarching financial leadership and strategic direction for the company's global financial activities. Directing all financial planning, analysis, and reporting, Garini ensures fiscal discipline and drives financial performance across all business segments. This executive role involves managing capital allocation, optimizing financial structures, and overseeing risk management to support Fresenius Kabi's long-term growth and operational objectives. By championing financial integrity and strategic investment, Alex Garini strengthens the company's economic resilience. The Executive Vice President & Chief Financial Officer's purview includes treasury, accounting, and financial strategy development. Garini's leadership is fundamental to maintaining Fresenius Kabi's financial stability and market position.
Rakesh Patel - Chief Operating Officer
Rakesh Patel, the Chief Operating Officer at Fresenius Kabi, executes the company's operational strategies across its global manufacturing and supply chain networks. Overseeing day-to-day operations, Patel ensures the efficient production and distribution of specialized medicines and technologies for infusion, transfusion, and clinical nutrition. This critical role involves optimizing manufacturing processes, managing logistics, and maintaining the highest standards of quality and compliance. By driving operational excellence, Rakesh Patel enhances Fresenius Kabi's capacity to serve healthcare providers and patients worldwide. The Chief Operating Officer's responsibilities include streamlining workflows, implementing best practices, and fostering collaboration across operational departments. Patel's leadership ensures the reliable delivery of essential healthcare products.
Scott Meacham - President, Pharmaceuticals (USA)
Scott Meacham, the President, Pharmaceuticals (USA) at Fresenius Kabi, leads the strategic direction and operational execution for the pharmaceutical division within the United States. Directing all aspects of the US pharmaceutical business, Meacham drives market growth, product development, and commercial success. This leadership role involves overseeing sales, marketing, and regulatory affairs to ensure Fresenius Kabi's pharmaceutical offerings meet the needs of the US healthcare market. By fostering strong relationships with healthcare providers and stakeholders, Scott Meacham enhances Fresenius Kabi's impact in the US. The President, Pharmaceuticals (USA)'s focus includes expanding market access and ensuring the availability of critical pharmaceutical products. Meacham's leadership is pivotal for the division's performance in the United States.
Takaaki Okado - Representative Director and President
Takaaki Okado, the Representative Director and President at Fresenius Kabi, directs the company's overall strategic vision and operational management. Overseeing global operations and corporate governance, Okado ensures alignment with Fresenius Kabi's mission to provide essential medicines and technologies for infusion, transfusion, and clinical nutrition. This leadership position involves guiding executive teams, fostering innovation, and driving sustainable growth across international markets. By championing strategic initiatives and operational excellence, Takaaki Okado strengthens Fresenius Kabi's global presence and impact. The Representative Director and President's responsibilities include setting corporate objectives and ensuring the highest standards of quality and patient care. Okado's leadership is instrumental in advancing Fresenius Kabi's position as a global healthcare leader.
Vaibhav Pimpale - Chief Technology Officer
Vaibhav Pimpale, the Chief Technology Officer at Fresenius Kabi, architects the company's technological vision and digital transformation initiatives. Directing all aspects of technology development and deployment, Pimpale ensures that Fresenius Kabi leverages cutting-edge solutions to enhance its specialized medicines and technologies for infusion, transfusion, and clinical nutrition. This role involves overseeing IT infrastructure, cybersecurity, and the integration of new digital platforms to streamline operations and improve patient outcomes. By driving innovation in technology, Vaibhav Pimpale supports the company's mission to advance healthcare globally. The Chief Technology Officer's strategic focus includes identifying emerging technologies and fostering a culture of technological excellence. Pimpale's leadership ensures that Fresenius Kabi remains at the forefront of technological advancement in the healthcare sector.
Katherine Luterek - Senior Business Development Manager & Chief Marketing Officer, Sterile Fill Finish
Katherine Luterek, the Senior Business Development Manager & Chief Marketing Officer, Sterile Fill Finish at Fresenius Kabi, spearheads strategic growth initiatives and market penetration for sterile fill finish operations. Directing both business development and marketing efforts, Luterek identifies new market opportunities and crafts compelling strategies to expand Fresenius Kabi's presence in this specialized sector. This dual role involves cultivating key partnerships, developing go-to-market plans, and enhancing brand visibility for sterile fill finish solutions. By driving strategic business development and impactful marketing campaigns, Katherine Luterek strengthens Fresenius Kabi's competitive position. The Senior Business Development Manager & Chief Marketing Officer's focus includes understanding market dynamics and aligning business objectives with customer needs. Luterek's leadership ensures the successful commercialization of sterile fill finish technologies.
Explore Leadership Teams in Manufacturing
Founded in 2003, Phibro Animal Health Corporation is a global manufacturer and marketer of animal health pharmaceuticals, animal nutrition, and performance products. The company is headquartered in Teaneck, New Jersey.
Company Leadership
SL
RF
MG
Alexion is a global biopharmaceutical company focused on the discovery, development, and commercialization of medicines for severe and life-threatening rare disorders. The company was established in 1992 and is headquartered in Boston, Massachusetts.
Company Leadership SG
PC
MO
YS
At Simtra, the company is dedicated to developing and manufacturing quality sterile injectable products to meet evolving patient needs. The company works with precision and transparency, setting high standards and paying attention to every detail, in order to ensure that the company makes your product right the first time, deliver it on time and meet your requirements in full. The company is made for this, with the company's extensive slate of services and product delivery options.
Company Leadership
TD
RG
Soft gelatin capsule products, liquid preparations, medicinal plasters, ointments, and creams are produced at the Gunung Putri Plant. In producing these products, Gunung Putri Plant implements an Integrated Management System and has obtained ISO 9001:2015, ISO 14001:2015, ISO 45001:2018 and ISO 22000:2018 certificates. Meanwhile, sterile injection products and solid preparations in the form of tablets and capsules are produced at the Citeureup Plant. The Citeureup Plant also implements an Integrated Management System and has obtained ISO 9001:2015, ISO 14001:2015, ISO 45001:2018, and SNI ISO/IEC 17025:2017 certificates. In running the Toll Manufacturing business, Darya-Varia collaborates with an affiliated company, PT Medifarma Laboratories, at the Cimanggis Depok Plant. The Company has been trusted by local business partners and both for the domestic and international markets for the Export & Toll Manufacturing business and conducts technology transfer, lab and pilot trials, stability studies, procurement of raw materials and packaging, and commercial production of high-quality finished goods. Darya-Varia always ensures the quality and safety of each product, so that all of its products are certified halal. All plant facilities owned by Darya-Varia have implemented the halal guarantee system. Blue Sphere Singapore Pte Ltd (BSSPL) owns 92.13% stake in Darya-Varia. For 45 years, Darya-Varia has continued to progress in providing high quality health facilities. Through the mission of "building a healthier Indonesia for everyone one person at a time", Darya-Varia is always committed to providing a variety of quality products with the right strategy for the health of the Indonesian people. DARYA VARIA
Company Leadership CH
Frequently Asked Questions Regarding Fresenius Kabi Top Executives and Leadership Team
Unlock more people and company data
